目的：探讨抗血管内皮生长因子(VEGF)药物治疗脉络膜新生血管(CNV)的疗效及对眼压、最佳矫正视力(BCVA)及多焦视网膜电图(mfERG)的影响。

方法：选取2015-02/2017-01在我院治疗的特发性CNV患者44例44眼，均给予玻璃体腔注射抗VEGF药物治疗，观察患者治疗前后BCVA、眼压、mfERG及中央视网膜厚度(CRT)的变化情况。

结果：治疗后1、3mo BCVA和CRT均较治疗前明显改善(P<0.05)，其中治疗后3mo BCVA和CRT分别为0.60±0.15和278.43±40.10μm，明显较治疗后1mo改善(P<0.05)。治疗后1、3mo和治疗前眼压比较无明显变化(P>0.05)。治疗后1、3mo Ring1、Ring2和Ring4 NI-P1振幅密度均较治疗前提高(P<0.05)； 治疗后3mo，Ring3 NI-P1振幅密度均较治疗前和治疗后1mo提高(P<0.05)； 治疗后1mo，Ring5 NI-P1振幅密度较治疗前和治疗后3mo均提高(P<0.05)； 治疗后1、3mo和治疗前Ring6 NI-P1振幅密度比较无明显变化(P>0.05)。

结论：抗VEGF药物治疗特发性CNV有较好的效果，能改善患者视力及黄斑区视网膜功能，降低视网膜厚度，且不影响眼压。

METHODS:Totally 44 cases(44 eyes)of idiopathic CNV patients treated in our hospital from February 2015 to January 2017 were selected. All patients were treated with intravitreal injection of anti-VEGF. BCVA, intraocular pressure, mfERG and central retinal thickness(CRT)were observed after treatment.

RESULTS: At 1 and 3mo after treatment, BCVA and CRT were significantly improved than those before treatment(P<0.05). At 3mo after treatment BCVA and CRT were 0.60±0.15 and 278.43±40.10μm, both significantly lower than that in 1mo after treatment(P<0.05). There was no significant change in intraocular pressure at 1 or 3mo after treatment than before treatment(P>0.05). At 1 and 3mo after treatment, amplitudes of Ring1, Ring2 and Ring4 NI-P1 were higher than those before treatment(P<0.05); at 3mo after treatment, the amplitude of Ring3 NI-P1 were higher than those before and 1mo after treatment(P<0.05); at 1mo after treatment, the amplitude of Ring5 NI-P1 were higher than those before and 3mo after treatment(P<0.05). The amplitude of Ring6 NI-P1 did not change significantly at 1 and 3mo after treatment, compared with before treatment(P>0.05).

CONCLUSION: Anti-VEGF drugs are effective in the treatment of idiopathic CNV, which can improve vision and macular retinal function, decrease the retinal thickness, and do not affect the intraocular pressure.